1-[(1-METHYL-1H-IMIDAZOL-2-YL)-PHENYL-METHYL]-PIPERAZINE
![]() |
- $160 - $777.32
- Product name: 1-[(1-METHYL-1H-IMIDAZOL-2-YL)-PHENYL-METHYL]-PIPERAZINE
- CAS: 104546-50-1
- MF: C15H20N4
- MW: 256.35
- EINECS:
- MDL Number:MFCD08688244
- Synonyms:1-[(1-METHYL-1H-IMIDAZOL-2-YL)-PHENYL-METHYL]-PIPERAZINE;1-[(1-methylimidazol-2-yl)-phenylmethyl]piperazine;Piperazine, 1-[(1-methyl-1H-imidazol-2-yl)phenylmethyl]-
3 prices
Selected condition:
Brand
- American Custom Chemicals Corporation
- Matrix Scientific
- Sigma-Aldrich
Package
- 500MG
- 1g
- ManufacturerAmerican Custom Chemicals Corporation
- Product numberCHM0083076
- Product description1-[(1-METHYL-1H-IMIDAZOL-2-YL)-PHENYL-METHYL]-PIPERAZINE 95.00%
- Packaging500MG
- Price$777.32
- Updated2021-12-16
- Buy
- ManufacturerMatrix Scientific
- Product number021590
- Product description1-[(1-Methyl-1H-imidazol-2-yl)-phenyl-methyl]-piperazine
- Packaging1g
- Price$495
- Updated2021-12-16
- Buy
- ManufacturerSigma-Aldrich
- Product numberPH018470
- Product description1-[(1-Methyl-1H-imidazol-2-yl)(phenyl)methyl]piperazine AldrichCPR
- Packaging1G
- Price$160
- Updated2022-05-15
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
American Custom Chemicals Corporation | CHM0083076 | 1-[(1-METHYL-1H-IMIDAZOL-2-YL)-PHENYL-METHYL]-PIPERAZINE 95.00% | 500MG | $777.32 | 2021-12-16 | Buy |
Matrix Scientific | 021590 | 1-[(1-Methyl-1H-imidazol-2-yl)-phenyl-methyl]-piperazine | 1g | $495 | 2021-12-16 | Buy |
Sigma-Aldrich | PH018470 | 1-[(1-Methyl-1H-imidazol-2-yl)(phenyl)methyl]piperazine AldrichCPR | 1G | $160 | 2022-05-15 | Buy |
Properties
Boiling point :438.5±45.0 °C(Predicted)
Density :1.17±0.1 g/cm3(Predicted)
pka :8.91±0.10(Predicted)
Density :1.17±0.1 g/cm3(Predicted)
pka :8.91±0.10(Predicted)
Safety Information
Symbol(GHS): |
![]() |
|||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | |||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||
Precautionary statements: |
|